Overview

An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Patients With Type II Diabetes

Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
This study will examine the ability of olmesartan medoxomil to lower the blood pressure of patients with Type II diabetes and high blood pressure. The medication being tested has been approved by the FDA for the treatment of high blood pressure.
Phase:
Phase 4
Details
Lead Sponsor:
Daiichi Sankyo Inc.
Daiichi Sankyo, Inc.
Treatments:
Angiotensin-Converting Enzyme Inhibitors
Hydrochlorothiazide
Olmesartan
Olmesartan Medoxomil